Year All2024202320222021202020192018201720162014201320112010 October 30, 2020 Rhythm Pharmaceuticals Announces Publication of Results from Phase 3 Clinical Trials of Setmelanotide in The Lancet Diabetes & Endocrinology October 28, 2020 Rhythm Pharmaceuticals Appoints Jennifer Chien as Executive Vice President, Head of North America September 14, 2020 Rhythm Pharmaceuticals Appoints Yann Mazabraud as Executive Vice President, Head of International September 9, 2020 Rhythm Pharmaceuticals to Present at Investor Conferences in September August 6, 2020 Rhythm Pharmaceuticals to Present Virtually at Canaccord Genuity 40th Annual Growth Conference August 3, 2020 Rhythm Pharmaceuticals Reports Second Quarter 2020 Financial Results July 27, 2020 Rhythm Pharmaceuticals Announces Appointment of Joseph Shulman as Senior Vice President of Technical Operations July 20, 2020 Rhythm Pharmaceuticals Announces Appointment of David Meeker, M.D., as Chief Executive Officer July 16, 2020 Rhythm Pharmaceuticals Announces Publication of Results from Phase 2 Study of Setmelanotide in Bardet-Biedl Syndrome in Diabetes, Obesity and Metabolism July 1, 2020 Rhythm Pharmaceuticals Receives Rare Pediatric Disease Designation from U.S. Food and Drug Administration for Setmelanotide for Treatment of POMC and LEPR Deficiency Obesities
October 30, 2020 Rhythm Pharmaceuticals Announces Publication of Results from Phase 3 Clinical Trials of Setmelanotide in The Lancet Diabetes & Endocrinology
October 28, 2020 Rhythm Pharmaceuticals Appoints Jennifer Chien as Executive Vice President, Head of North America
September 14, 2020 Rhythm Pharmaceuticals Appoints Yann Mazabraud as Executive Vice President, Head of International
August 6, 2020 Rhythm Pharmaceuticals to Present Virtually at Canaccord Genuity 40th Annual Growth Conference
July 27, 2020 Rhythm Pharmaceuticals Announces Appointment of Joseph Shulman as Senior Vice President of Technical Operations
July 20, 2020 Rhythm Pharmaceuticals Announces Appointment of David Meeker, M.D., as Chief Executive Officer
July 16, 2020 Rhythm Pharmaceuticals Announces Publication of Results from Phase 2 Study of Setmelanotide in Bardet-Biedl Syndrome in Diabetes, Obesity and Metabolism
July 1, 2020 Rhythm Pharmaceuticals Receives Rare Pediatric Disease Designation from U.S. Food and Drug Administration for Setmelanotide for Treatment of POMC and LEPR Deficiency Obesities
